// App-Quantinova.ai

4181 : Prognosis of patients with mid-range left ventricular ejection fraction treated with PCI: insight from the global leaders study.

Researchers

Presenter

  • P Chichareon

Principal Investigators

  • R Modolo

  • N Kogame

  • M Tomaniak

  • E Teiger

  • EF Quintella

  • M Almeida

  • C Hamm

  • G Steg

  • P Juni

  • P Vranckx

  • M Valgimigli

  • S Windecker

  • Y Onuma

  • PW Serruys

Medical Centers

  • Amsterdam University Medical Center - Amsterdam - Netherlands (The)

  • Erasmus University Medical Center, Rotterdam, Netherlands

  • University Hospital of Henri Mondor, APHP, Creteil, France

  • Instituto Estadual Cardiologia Aloisio De Castro - Rio de Janeiro - Brazil

  • Hospital de Santa Cruz, CHLO, Carnaxide, Portugal

  • Kerckhoff Heart Center, Bad Nauheim, Germany

  • GH Bichat Claude Bernard, Paris, France

  • St. Michael's Hosp, Toronto, ON, Canada

  • Virga Jesse Hospital - Hasselt - Belgium

  • Preventive Cardiology & Sports Medicine

  • University College London - London - United Kingdom of Great Britain & Northern Ireland

Locations

  • N/A

Companies

  • N/A

Study Components

Therapeutic Area

  • Central Nervous System (CNS)

  • Cardiovascular (CVS)

  • Blood/haematological Diseases

  • Pulmonary/Respiratory Diseases

Disease

  • Heart failure with mid-range Ejection Fraction

  • Myocardial infarction

  • Congestive heart failure

  • Venous thrombosis

  • Stroke

Biomarkers

  • N/A

Drug/Treatment

  • Biolimus A9

Outcome

  • N/A

Study Design

  • Randomized

  • Multicenteric

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved